CNCT19 cell therapy for relapsed or refractory ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests an infusion of modified immune cells (CNCT19) in people with acute lymphoblastic leukemia (ALL) that has come back or did not respond to treatment. It may help by targeting leukemia cells that have a specific marker called CD19.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 65 and be willing to sign consent
- Have relapsed or refractory acute lymphoblastic leukemia (ALL) based on specific timing and prior treatment history
- Have CD19 found on leukemia cells in blood or bone marrow within 3 months of starting the study
- Have at least 5% lymphoblasts in a bone marrow sample at screening
- Be well enough to participate (ECOG 0 to 1) and have adequate liver, kidney, and blood clotting lab results
- Not have certain recent treatments: no chemotherapy in the last 2 weeks before the CNCT19 infusion (with detailed exceptions) and no prior CAR-T therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of immunotherapy called CAR-T-19 for children and young adults up to age 25 whose B-ALL has returned or is not responding to standard treatments. The CAR-T cells are engineered to find and destroy leukemia cells that have the CD19 protein.
This early-stage trial tests a personalized immune-cell treatment called CNCT19 in children and teens whose leukemia (ALL) has come back or not responded to prior therapy. It may help the immune system recognize and attack leukemia cells that carry CD19.
This trial tests a CAR-T cell therapy (CNCT19) for people with B-cell acute lymphoblastic leukemia (B-ALL) who still have a tiny amount of cancer cells after standard treatment. The goal is to see if this therapy can clear those remaining cancer cells.
This trial tests a CAR-T cell therapy called Inaticabtagene Autoleucel (CNCT19) for people with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) who are in their first complete remission. It aims to see if this treatment can help prevent relapse without a stem cell transplant.
Hear when a new Relapsed or Refractory Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.